Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 3
1969 1
1973 1
1974 1
1979 2
1980 1
1988 1
1989 1
1992 1
1996 1
1998 3
2000 6
2001 3
2002 2
2004 5
2005 5
2006 4
2007 7
2008 7
2009 7
2010 10
2011 9
2012 10
2013 13
2014 10
2015 19
2016 19
2017 11
2018 21
2019 30
2020 28
2021 36
2022 30
2023 33
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

311 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Kozlinska
Page 1
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
Smalley I, Chen Z, Phadke M, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Smalley I, et al. Clin Cancer Res. 2021 Jul 15;27(14):4109-4125. doi: 10.1158/1078-0432.CCR-21-1694. Epub 2021 May 25. Clin Cancer Res. 2021. PMID: 34035069 Free PMC article.
Inna L. Soroka.
[No authors listed] [No authors listed] Angew Chem Int Ed Engl. 2022 Feb 21;61(9):e202117860. doi: 10.1002/anie.202117860. Epub 2022 Jan 10. Angew Chem Int Ed Engl. 2022. PMID: 35014133
"I am waiting for the day when someone will discover the way to create metamaterials, artificial structures with negative refractive index, that will operate in the optical wavelength range If I were not a scientist, I would be a human resource specialist since I like working wit …
"I am waiting for the day when someone will discover the way to create metamaterials, artificial structures with negative refractive index, …
Pain in women.
Belfer I. Belfer I. Agri. 2017 Apr;29(2):51-54. doi: 10.5505/agri.2017.87369. Agri. 2017. PMID: 28895988 Free article. Review.
Reply to Inna Sokolova.
Fisher D, Parisis N. Fisher D, et al. EMBO Rep. 2016 Jul;17(7):932. doi: 10.15252/embr.201642765. Epub 2016 Jun 13. EMBO Rep. 2016. PMID: 27296279 Free PMC article.
TLR2-mediated innate immune priming boosts lung anti-viral immunity.
Girkin J, Loo SL, Esneau C, Maltby S, Mercuri F, Chua B, Reid AT, Veerati PC, Grainge CL, Wark PAB, Knight D, Jackson D, Demaison C, Bartlett NW. Girkin J, et al. Eur Respir J. 2021 Jul 1;58(1):2001584. doi: 10.1183/13993003.01584-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33303547 Free article.
BACKGROUND: We assessed whether Toll-like receptor (TLR)2 activation boosts the innate immune response to rhinovirus infection, as a treatment strategy for virus-induced respiratory diseases. METHODS: We employed treatment with a novel TLR2 agonist (INNA-X) prior to rhinov …
BACKGROUND: We assessed whether Toll-like receptor (TLR)2 activation boosts the innate immune response to rhinovirus infection, as a treatme …
Interactive neural-network-assisted screening. A clinical assessment.
Mango LJ, Radensky PW. Mango LJ, et al. Acta Cytol. 1998 Jan-Feb;42(1):233-45. doi: 10.1159/000331552. Acta Cytol. 1998. PMID: 9479346 Review.
Estimates for another relative yield metric, representing INNA use in a primary screening mode (non-United States studies), show 18-40% increases in the yield of abnormality with INNA screening when compared with unassisted screening alone. CONCLUSION: The findings …
Estimates for another relative yield metric, representing INNA use in a primary screening mode (non-United States studies), show 18-4 …
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
311 results